arrow
B

Bruce Strober

Yale School of Medicine
H指数:65
被引数:1.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy of Apremilast in Patients with Psoriasis with Limited Skin Involvement, Including High-Impact Site Involvement: A Pooled Analysis of Six Trials

阿普米ast在皮肤受累范围有限且包括重要部位受累的银屑病患者中的疗效:六项试验的合并分析

2026-10-020
OA
Deucravacitinib 5-Year Safety and Efficacy Results in Plaque Psoriasis: A Phase 3 Open-Label Extension of Randomized Clinical Trials

德卡鲁昔替尼治疗斑块状银屑病5年安全性和有效性结果:一项随机临床试验的III期开放标签扩展研究

2026-08-070
OA
Bridging psoriasis and metabolic comorbidities: Toward comprehensive patient management. Priorities from the International Psoriasis Council

银屑病与代谢性合并症的联系:迈向全面的病人管理。国际银屑病委员会的优先事项

2026-07-250
OA
Summary of Research: Apremilast in Japanese Patients with Palmoplantar Pustulosis: A Randomized, Phase 3 Trial

研究摘要:Apremilast在日本掌跖脓疱病患者中的疗效:一项随机、III期临床试验

2025-12-130
OAAI
Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial

Apremilast在日本掌跖脓疱病患者中的疗效:一项随机、III期临床试验

2025-11-260
OAAI
Joint Position Statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on Routine Testing for Latent Tuberculosis Infection Prior To and During Treatment of Psoriasis Patients with IL-17 or IL-23 Inhibitors

中华银屑病基金会医学委员会与国际银屑病委员会联合立场声明:关于在应用IL-17或IL-23抑制剂治疗银屑病患者前及治疗期间常规检测潜伏性结核感染的说明

2025-11-170
OAAI
Roflumilast Cream 0.3% in Patients with Chronic Plaque Psoriasis: Pooled PASI and PASI-HD Results from the DERMIS Phase III Trials

0.3%罗氟司特乳膏在慢性斑块状银屑病患者中的研究:DERMIS III期试验合并的PASI和PASI-HD结果

2025-10-240
OA
Establishing Consensus on Defining Failure of Topical Therapy in Psoriasis: Recommendations from the International Psoriasis Council

建立银屑病外用治疗效果不佳的定义共识:国际银屑病委员会的建议

2025-09-110
PREAI
Benefits of Earlier Apremilast Initiation in Patients with Psoriasis and Limited Skin Involvement: Results from a Real-World Retrospective Study

早期阿普米ласт启动在银屑病伴有限皮肤受累患者中的获益:一项真实世界回顾性研究的结果

2025-08-060
OA
Real-World Skin Clearance and Quality of Life with risankizumab in Patients with Psoriasis with Moderate Skin Involvement and Those Eligible for Systemic Therapy Per International Psoriasis Council Classification

真实世界中,中度皮肤受累的银屑病患者以及根据国际银屑病协会分类有资格接受系统性治疗的患者使用risankizumab后的皮肤清除效果和生活质量。

2025-07-020
OA
International Psoriasis Council psoriasis disease severity reclassification: Update on validity, acceptance, and implementation

国际银屑病协会银屑病疾病严重程度重新分类:有效性、接受度和实施情况的更新

2025-06-060
OAAI